Massimo Breccia and Italy - Free people check

(1 - 10 from 14

)

6th International Symposium on Acute Promyelocytic Leukemia |...

www.allcongress.com

Lionel Adés (France) Myriam Alcalay (Italy) Sergio Amadori (Italy) Giuseppe Avvisati (Italy) Nancy Berliner (USA) Massimo Breccia (Italy) Alan K. Burnett (UK)

WikiGenes - Massimo Breccia

www.wikigenes.org

Massimo Breccia. Dipartimento di Biotecnologie Cellulari ed Ematologia. University La Sapienza. Italy. [. Name/email consistency: high.

Adherence and future discontinuation of tyrosine kinase inhibitors in...

www.sciencedirect.com

Massimo Breccia. Search for articles by this author Affiliations. Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;

crihem - Editorial board | Hindawi

www.hindawi.com

Massimo Breccia, Universita degli Studi di Roma La Sapienza, Italy Sylvain Choquet , Hôpital de la Pitié-Salpêtrière, France Gandhi Damaj , Centre Hospitalier Universitaire de Caen, France

Disappearance of fibrosis in secondary myelofibrosis after...

link.springer.com

Massimo Breccia (1) Author Affiliations. 1. Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6Rome, Italy ...

Oalib search

www.oalib.com

S3291 Massimo Breccia, Giuliana Alimena Department of Cellular Biotechnology and Hematology, “Sapienza” University of Rome, Italy ...

All web results to the name "Massimo Breccia"

Frontiers | BCR-ABL1 Doubling-Times and Halving-Times May ...

www.frontiersin.org

Aug 13, · Massimo Breccia, Sapienza University of Rome, Italy. Reviewed by: Valentin Garcia-Gutierrez, Ramón y Cajal University Hospital, Spain Rehan Khan, Mayo Clinic Arizona, United States Alejandro Majlis, Las Condes Clinic, Chile.

Systematic review of dasatinib in chronic myeloid leukemia | OTT

www.dovepress.com

Systematic review of dasatinib in chronic myeloid leukemia Massimo Breccia, Adriano Salaroli, Matteo Molica, Giuliana Alimena Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy Abstract: Dasatinib is a dual tyrosine kinase inhibitor active against ABL and Src family kinases, and is approved for the treatment of chronic myeloid leukemia (CML) patients in ...

The Real-World Role for Second-Line Ponatinib in CML Is ...

www.cancertherapyadvisor.com

Aug 07, · “Ponatinib was put on hold by FDA for the increased risk of cardiovascular events,” Massimo Breccia, MD, of Sapienza University of Rome in Italy, told Cancer Therapy Advisor.